Drug – bio-affecting and body treating compositions – Addiction – Tobacco
Patent
1996-10-03
1999-03-09
Harrison, Robert H.
Drug, bio-affecting and body treating compositions
Addiction
Tobacco
131270, 131347, 131359, 514343, 514958, A24B 1500, A61K 972, A61K 31465
Patent
active
058801642
ABSTRACT:
A smoking material is provided that is useful to alleviate the symptoms of the tobacco withdrawal syndrome comprising an amount of continine or a pharmaceutical acceptable salt thereof in combination with a non-toxic vegetable material, which amount is effective to reduce or eliminate at least one of the symptoms of tobacco withdrawal syndrome in a human when the smoking material is smoked by a human.
REFERENCES:
patent: 2981641 (1961-04-01), O'Neill
patent: 3048520 (1962-08-01), McKennis, Jr. et al.
patent: 3821960 (1974-07-01), Egri
patent: 3870794 (1975-03-01), Hutchinson et al.
patent: 4038993 (1977-08-01), Geiss et al.
patent: 4153063 (1979-05-01), Roselius et al.
patent: 4289147 (1981-09-01), Wildman et al.
patent: 4598720 (1986-07-01), Gabriel
patent: 4621074 (1986-11-01), Bourne
patent: 4657032 (1987-04-01), Door et al.
patent: 4848373 (1989-07-01), Lenkey
patent: 5643928 (1997-07-01), Keenan
patent: 5747512 (1998-05-01), Keenan et al.
patent: 5776956 (1998-07-01), Rolf
Jarvik et al. Pharmacological Treatent of Tobacco Dependence. Pharmacol-Biochem-Behav. vol. 30, No. 1, pp. 279-294. (May 1988).
Heatherton et al. The Fagerstrom Test for Nicotine Dependence: A Revision of the Fagerstrom Tolerance Questionaire. Br.-J-Addict., 86(9), pp. 1119-1127. (Sep. 1999).
Pomerleau et al. Reliability of the Fagerstrom Tolerance Questionaire and the Fagerstrom Test for Nicotine Dependence. Addict-behav. 19(1) pp. 33-39/ (Jan. 1994-Feb. 1994).
"American Psychiatric Assoc., Diagnostic and Statistical Manual of Mental Disorders",Washington, DC (3rd ed.), pp. 159-160, 176-178 (1980).
"Methyl Pyrrolidone Preparation Oxidatio Methyl Pyrrolidone Potassium Sodium Ferricyanide Aqueous Solution", Database WPI, Derwent Publications Ltd., London, GB; AN 80-28065c, XP002005722 & JP,A,55 031 005 (Japan Tobacco & Salt Pub), (1988).
"The Health Consequences of Smoking: Nicotine Addiction. A Report to the Surgeon General", US Gov't Print. Off., Washington, DC, DHHS Publication No. (CDC) 88-8406 (1988), .
Beckett, A.H., et al., "A possible relationship between pKal and lipid solubility and the amounts secreted in urine to some tobacco alkaloids give to man", J. Pharma. Pharmacol., 24, 115-120 (1972).
Benowitz, N.L., et al., "Cotinine disposition and effects", Clin Pharmacol. Ther., 34, 604-611 (Nov. 1983).
Bowman, E.R., et al., "Studies on metabolism of (-) -Continine in the Human", J. Pharmacol. Exp. Ther., 135, 306-311 (1962).
Curvall, M., et al., "The pharmacokinetics of continine in plasma and saliva from non-smoking healthy volunteers", Eur. J. Clin. Pharmacol., 38 281-287, (1990)
De Schepper, P.J., et al., "Kinetics of Cotinine after Oral and Intravenous Administration to man", Eur. J. Clin. Pharmacol., 31, 583-588.
Gabrielsson, J., et al., "Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat", J. Pharmacokinetics Biopharmaceutics, 15, 583-599 (1987).
Goldberg, S.R., et al., "Nictone and Some Related Compounds: Effects on Schedule-Controlled Behavior and Discriminative Properites in Rates", Psychopharmacology, 97, 295-302 (1989).
Hughes, J., et al., "Effects of Abstinence from Tobacco, A Critical Review", Research Advances in Alcohol and Drug Problems, 10, Plenum Press, New York; Lynn Kolowski, ed; 317-398 (1990).
Keenan, R.M., et al., "Reply to Mr. Foulds", Clin. Pharmacol. Ther., 57, 95-97, (Jan., 1995).
Liberto, J.G., et al., "Cotinine in the Treatment of Cigarette Smoking", J. Addictive Dis., 14, Abstract No. 11A, p. 147, (1995).
Mckennis, H., et al., "N-Methylation of Nicotine and Cotinine in Vivo", J. Biol. Chem., 238, 719-723 (1963).
Risner, M.E., et al., "Effects of Nicotin, Cocaine and Some of their Metabolites on Schedule-Controlled Responding by Beagle Dogs and Squirrel Monkeys", J. Pharmacol. Exp. Ther., 234, 113-119 (1985).
Scherer, G., et al., "Pharmacokinetics of Nicotone, Cotinine, and 3"- Hydroxzycotinine in Cigarette Smokers", Klin. Wochenschr., 66 (Suppl XI), 5-11 (1988).
Takada, K., et al., "Discriminitive stimulus effects of intravenous 1-nicotine and nicotine analogs or metabolites on squirrel monkeys", Psychopharmacology, 99, 208-212 (1989).
Keenan, R.M., et al., "Pharmacodynamic Effects of Cotinine in Abstinent Cigarette Smokers", Clin. Pharmacol. Ther., 55, 581-590, (May, 1994).
Yamamoto, K.I., et al., "Nicotine-Induced EEG and Behavioral Arousal", Int. J. Neuropharmacol., 4, 359-373 91965).
Harrison Robert H.
LecTec Corporation
LandOfFree
Nicotine-free smoking material does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nicotine-free smoking material, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotine-free smoking material will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1321614